Why is "Abiraterone" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-05 04:08:01
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). It should either be used following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is taken by mouth.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer | JCO Global Oncology - ASCO Publications
-
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial - Nature
-
Niraparib and Abiraterone Acetate Nets European Approval in BRCA1/2-Mutated mHSPC - OncLive
-
Frontline Abiraterone/Olaparib Doubles PFS in Biomarker-Selected mCRPC - Targeted Oncology
-
BRCAAway: Abiraterone/olaparib shows survival gain in mCRPC - Urology Times
-
FDA Approves Niraparib and Abiraterone With Prednisone for BRCA-mutated Prostate Cancer - Oncology News Central
-
Can a Genetic Variant Affect the Efficacy of Abiraterone? - The ASCO Post
-
England Backs Wider Use of Abiraterone for Prostate Cancer - Medscape
-
Oric to advance prostate cancer drug to Phase III trials - Clinical Trials Arena
-
Half-Dose Abiraterone Effective & Safe for PCa Suppression - Physician's Weekly
-
Thousands more men in England offered abiraterone, one of our prostate cancer treatment breakthroughs - Cancer Research UK - Cancer News
-
Niraparib/Abiraterone Acetate Dual Action Tablet Approaches EU Approval in mHSPC With BRCA1/2 Mutations - OncLive
-
Lower dose of abiraterone shows comparable efficacy to standard dose for prostate cancer - Urology Times
-
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC - Targeted Oncology
-
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study - Nature
-
PARP Inhibition Plus Abiraterone Shows Benefit in HRR-Altered Metastatic Castration-Sensitive Prostate Cancer - The ASCO Post
-
Capivasertib Added to Abiraterone Extends rPFS in PTEN-Deficient mHSPC - OncLive
-
EU agency recommends expanded approval of niraparib/abiraterone dual tablet in mHSPC - Urology Times
-
FDA Approves Niraparib/Abiraterone Acetate Plus Prednisone for BRCA2+ mCSPC - OncLive
-
Apalutamide vs Abiraterone Acetate RWE Outcomes in mCSPC - Urology Times
-
Abiraterone receives new NICE approval in ‘significant shift’ - The Pharmaceutical Journal
-
Life-extending prostate cancer drug to be offered to thousands in England - BBC
-
Real-World Overall Survival with Apalutamide Versus Abiraterone in mHSPC - Benjamin Lowentritt - UroToday
-
Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC - Urology Times
-
Niraparib Plus Abiraterone in HRR-Mutant Metastatic Castration-Sensitive Prostate Cancer - The ASCO Post
-
Niraparib/Abiraterone Is Effective for HRR+ Metastatic Castration-Sensitive Prostate Cancer - OncLive
-
AMPLITUDE: HRQOL is maintained with niraparib plus abiraterone - Urology Times
-
FDA Greenlights Niraparib/Abiraterone Acetate With Prednisone in mHSPC - Oncology Nursing News
-
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation - Beyond the Abstract - UroToday
-
Capivasertib prolongs rPFS in PTEN-deficient hormone-sensitive prostate cancer - Urology Times
-
Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial - Fred Saad - UroToday
-
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC - Urology Times
-
EU Approval Is Sought for Niraparib/Abiraterone Acetate Dual-Action Tablet in mHSPC With HRR Gene Alterations - OncLive
-
Analysis of the Phase III CAPItello-281 Trial: Capivasertib plus Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer - Daniel George - UroToday
-
Drug-Induced Liver Injury Caused by Abiraterone Acetate in Patients With Prostate Cancer - Cureus
-
Real-World Outcomes of Upfront Abiraterone in Metastatic Castration-Sensitive Prostate Cancer Patients at a Tertiary Care Hospital - Cureus
-
Qiling decoction enhances the anti-tumor activity of abiraterone acetate by up-regulating miR-143 expression in abiraterone acetate-resistant prostate cancer cells - Frontiers
-
Dr Attard on Niraparib/Abiraterone Acetate Plus Prednisone in mCRPC With HRR Alterations - OncLive
-
FDA Approves Niraparib Plus Abiraterone for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer - Oncodaily
-
NICE U-Turn Expands Access to Prostate Cancer Drug - Medscape
-
Lower dose of abiraterone acetate as effective for prostate cancer treatment - EurekAlert!
-
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability - Urology Times
-
The ICR welcomes NHS decision to grant lifesaving prostate cancer drug to men in England - The Institute of Cancer Research
-
NHS expands access to prostate cancer drug in England to save thousands of lives - The Guardian
-
Formulation Matters: Tailoring Abiraterone Dosing for Optimal Absorption and Tolerability - Urology Times
-
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC - cancernetwork.com
-
AMPLITUDE Trial: Niraparib Plus Abiraterone in HRR-Mutated mCSPC - Oncodaily
-
UCL research leads to new NHS treatment for high‑risk prostate cancer | UCL News - UCL - University College London
-
Managing Abiraterone Intolerance: Alternative Dosing Strategies in Practice - Urology Times
-
Neeraj Agarwal: Abemaciclib Plus Abiraterone vs Abiraterone in mCRPC Prostate Cancer - Oncodaily
-
Abiraterone Acetate: Generic and Branded Options - Urology Times
-
NHS England recommends extension of drug to treat non-metastatic prostate cancer - The Pharmaceutical Journal
-
“Abiraterone gave my husband time to live life to the full” - Sue's story - The Institute of Cancer Research
-
NICE relents, ending postcode access to prostate cancer drug - pharmaphorum
-
A Super-Enhancer-Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration-Resistant Prostate Cancer - Wiley
-
Nicholas D. James, PhD, FRCP, MBBS, on Using AI to Identify Benefit From Prostate Cancer Therapy - The ASCO Post
-
'Very Impressive' Survival With Combo in First-Line Prostate Cancer Study - MedPage Today
-
Christine Ibilibor, MD, highlights study of racial differences in abiraterone use - Urology Times
-
NICE U-turn allows NHS funding of Pfizer's Talzenna for prostate cancer - FirstWord Pharma
-
Is targeted therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer on the horizon? - ESMO Daily Reporter
-
ASCO 2025: AI test determines best prostate cancer treatment – which could save NHS money - The Institute of Cancer Research
-
Reducing the side effects of hormone therapy for prostate cancer: the ENHANCE trial - Cancer Research UK - Cancer News
-
Case study: 69-year-old Black man with mHSPC - Urology Times
-
AI test to determine best prostate cancer treatment could save lives and money | UCL News - UCL - University College London
-
Akeega Approved for BRCA2-Mutated Prostate Cancer - MedPage Today
-
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat - GlobeNewswire
-
NHS to offer life-extending prostate cancer drug to thousands of men in England - openaccessgovernment.org
-
Life-extending prostate cancer drug to be made available to thousands more patients - The Independent
-
New AI test can predict which men will benefit from prostate cancer drug - The Guardian
-
Men ‘condemned to die’ as NHS won’t buy cheap prostate cancer drug - The Times
-
Is Niraparib Combo the New Standard for Certain Prostate Cancers? - Oncology News Central
-
Dr Morgans Provides Prostate Cancer Updates From ASCO 2025 - Targeted Oncology
-
Thousands of men with prostate cancer to receive life extending drug - National Health Executive
-
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer - NEJM Evidence
-
Exeter research into prostate cancer drug could help thousands and save the NHS millions - University of Exeter News
-
Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients - Nature
-
“There has never been a more exciting time for cancer research than today” – Peter’s prostate cancer story - The Institute of Cancer Research
-
Evolving role of abiraterone: metastatic castrate resistant prostate cancer (video) - the limbic
-
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer - Nature
-
European Commission approves AKEEGA (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC) - Irish Medical Times
-
Vedang Murthy: Abiraterone for High-Risk Prostate Cancer in the PSMA-PET Era - STAMPEDE-Like Cohort Analysis - Oncodaily
-
AI to help more patients get prostate cancer drug that cuts risk of death - The Independent
-
Abiraterone, Prednisone, Apalutamide Improves Prostate Cancer Outcomes, Leaves HRQoL Unaffected - Targeted Oncology
-
Over a decade of abiraterone: the drug that revolutionised advanced prostate cancer care - The Institute of Cancer Research
-
Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients - Nature
-
Fatal fulminant hepatitis in a patient taking abiraterone acetate: a case report - Frontiers
-
Drug costing just £2.50 will extend life of prostate cancer patients - The Times
-
The ArteraAI Prostate Test Enhanced with New Insights for Higher Risk Patients with Localized Prostate Cancer - BioSpace
-
Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug - National Cancer Institute (.gov)
-
Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer - Nature
-
Case Report: Abiraterone in brain metastases from prostate cancer - Frontiers
-
Lynparza plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer - AstraZeneca
-
Abiraterone: Life-saving Prostate cancer drug to be accessible for thousands in UK - Jang
-
Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p - Nature
-
Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison - Nature
-
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer - NEJM
-
Prostate cancer patients to benefit from cheaper drugs - The Telegraph
-
European Commission approves AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC) - The Manila Times
-
Abiraterone Improves Survival for Some Men with Hormone-Sensitive Prostate Cancer - National Cancer Institute (.gov)
-
Treatment with abiraterone significantly improves survival in advanced prostate cancer - Harvard Health
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.